These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15504988)

  • 1. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone.
    Sarker A; Semple RK; Dinneen SF; O'Rahilly S; Martin SC
    Diabetes Care; 2004 Nov; 27(11):2577-80. PubMed ID: 15504988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
    Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
    Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
    Keidar S; Guttmann H; Stam T; Fishman I; Shapira C
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1192-4. PubMed ID: 17636555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
    Shetty C; Balasubramani M; Capps N; Milles J; Ramachandran S
    Diabet Med; 2007 Jan; 24(1):94-7. PubMed ID: 17227331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.
    Gutschi LM; Malcolm JC; Favreau CM; Ooi TC
    Ann Pharmacother; 2006 Sep; 40(9):1672-6. PubMed ID: 16912247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones and lowered HDL cholesterol.
    Savage RL; Kiuru A
    Diabetes Care; 2005 Sep; 28(9):2329-30. PubMed ID: 16123514
    [No Abstract]   [Full Text] [Related]  

  • 8. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Proteomics Identifies Paraoxonase/Arylesterase 1 (PON1) and Apolipoprotein Cs as Potential Risk Factors for Hypoalphalipoproteinemia in Diabetic Subjects Treated with Fenofibrate and Rosiglitazone.
    Ronsein GE; Reyes-Soffer G; He Y; Oda M; Ginsberg H; Heinecke JW
    Mol Cell Proteomics; 2016 Mar; 15(3):1083-93. PubMed ID: 26667175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
    Lebovitz HE; Kreider M; Freed MI
    Diabetes Care; 2002 May; 25(5):815-21. PubMed ID: 11978674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage.
    Rennings AJ; Smits P; Stewart MW; Tack CJ
    Diabetologia; 2010 Sep; 53(9):1856-66. PubMed ID: 20499046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China].
    Zhu XX;
    Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):636-9. PubMed ID: 14514393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No improvement of high-density lipoprotein (HDL) vasorelaxant effect despite increase in HDL cholesterol concentration in type 2 diabetic patients treated with glitazones.
    Perségol L; Duvillard L; Monier S; Brindisi MC; Bouillet B; Petit JM; Vergès B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E2015-9. PubMed ID: 25137425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.
    van Wijk JP; de Koning EJ; Castro Cabezas M; Rabelink TJ
    Diabetes Care; 2005 Apr; 28(4):844-9. PubMed ID: 15793183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
    Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinedione-induced edema in patients with heart failure.
    Stroup JS
    Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
    [No Abstract]   [Full Text] [Related]  

  • 19. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.
    Carreón-Torres E; Rendón-Sauer K; Monter-Garrido M; Toledo-Ibelles P; Gamboa R; Menjivar M; López-Marure R; Luc G; Fievet C; Cruz D; Vargas-Alarcón G; Pérez-Méndez O
    Clin Chim Acta; 2009 Mar; 401(1-2):37-41. PubMed ID: 19036342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone-induced anasarca without heart failure: capillary leakage?
    Dagdelen S; Kurt M; Aydin K; Bayraktar M
    Hormones (Athens); 2008; 7(2):180-3. PubMed ID: 18477557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.